26.77
0.39 (1.48%)
| Previous Close | 26.38 |
| Open | 24.84 |
| Volume | 9,355 |
| Avg. Volume (3M) | 318,150 |
| Market Cap | 1,198,605,184 |
| Price / Earnings (Forward) | 104.17 |
| Price / Sales | 52.79 |
| Price / Book | 3.00 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -11,831.05% |
| Diluted EPS (TTM) | -1.78 |
| Quarterly Revenue Growth (YOY) | -30.90% |
| Total Debt/Equity (MRQ) | 6.25% |
| Current Ratio (MRQ) | 32.19 |
| Operating Cash Flow (TTM) | -74.10 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -30.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Septerna, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 105.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp V, Llc | 30 Sep 2025 | 6,215,591 |
| Trv Gp Vi, Llc | 30 Sep 2025 | 4,211,659 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Jones Trading, 60.63%) | Buy |
| Median | 34.00 (27.01%) | |
| Low | 28.00 (Wells Fargo, 4.60%) | Buy |
| Average | 34.60 (29.25%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 25.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 23 Dec 2025 | 43.00 (60.63%) | Buy | 28.23 |
| Raymond James | 19 Dec 2025 | 38.00 (41.95%) | Buy | 29.58 |
| Truist Securities | 15 Dec 2025 | 34.00 (27.01%) | Buy | 27.18 |
| Wells Fargo | 14 Nov 2025 | 28.00 (4.59%) | Buy | 23.27 |
| HC Wainwright & Co. | 11 Nov 2025 | 30.00 (12.07%) | Buy | 19.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer |
| 17 Dec 2025 | Announcement | Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2025 | Announcement | Septerna to Participate in 8th Annual Evercore Healthcare Conference |
| 10 Nov 2025 | Announcement | Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Septerna to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |